[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-355108-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-355108-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","gut-microbiota-drives-cancer-evolution-and-therapy-resistance","Gut microbiota drives cancer evolution and therapy resistance","","The gut microbiota functions as a key regulator of host immunity and is increasingly linked to cancer initiation, progression, and therapeutic outcomes. Through metabolic reprogramming, generation of virulence factors, and remodeling of the immune microenvironment, microbiota alterations can shape tumor evolution. Despite progress with multi-target inhibitors and immune checkpoint blockers, therapy resistance, low response rates, and toxicity remain major obstacles. This review consolidates evidence that microbiota modulation may improve efficacy by restoring ecological balance, strengthening anti-cancer immunity, and correcting metabolic dysregulation.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/gut-microbiota-drives-cancer-evolution-and-therapy-resistance/355108/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/gut-microbiota-drives-cancer-evolution-and-therapy-resistance/355108.png","ImageObject",300,407,{"name":42,"@type":43},"Ezra","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-18","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How does gut microbiota influence cancer development and progression?","Question",{"text":63,"@type":64},"Gut microbiota affects initiation and progression via metabolic reprogramming, virulence factor production, and immune microenvironment remodeling that can promote a pro-tumorigenic context.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What factors contribute to therapy resistance according to this review?",{"text":68,"@type":64},"Microbiota-driven metabolic dysregulation and altered immune microenvironment can support tumor evolution and reduce responsiveness to therapies.",{"name":70,"@type":61,"acceptedAnswer":71},"What therapeutic strategies are proposed to overcome resistance?",{"text":72,"@type":64},"Strategies include modulating the microbiota by restoring ecological balance, enhancing anti-cancer immunity, and correcting metabolic dysregulation to improve clinical outcomes.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},355108,1790176326,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":112,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},1099514068035,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Min etal. Molecular Cancer (2026) 25:39 [https://doi.org/10.1186/s12943-025-02564-8](https://doi.org/10.1186/s12943-025-02564-8)  \nMolecular Cancer  \nREVIEW Open Access  \nGut microbiota drives cancer evolution and therapy resistance  \nSiwei Min1†, Yue Zhang2†, Hao Zhang3* and Qi Liu3*  \nAbstract  \nInitially recognized for its role in digestion, the gut microbiota is now acknowledged as a critical regulator of the host immune system. It influences not only the initiation and progression of cancer but also key therapeutic mechanisms through metabolic reprogramming, production of virulence factors, and remodeling of the immune microenvironment. Despite significant advancements in patient outcomes attributed to novel multi-target inhibitors and immune checkpoint blockers, several clinical challenges persist, including therapy resistance, low response rates, and considerable toxicity. The increasing recognition of the role of microbiota in oncology has positioned its modulation as a pivotal strategy influencing the efficacy and overall success of treatment. This review summarizes how alterations in the gut microbiota influence tumorigenesis, shape immune responses, and mediate resistance to cancer therapies. This study also explores therapeutic strategies designed to modulate the microbiota by restoring ecological balance, enhancing anti-cancer immunity, or rectifying metabolic dysregulation to overcome therapy resistance and improve clinical outcomes. These approaches present a novel paradigm for addressing the challenge of drug resistance in cancer therapy.  \nKeywords Gut microbiota, Metabolic reprogramming, Immunotherapy resistance, Immune microenvironment, Therapy resistance, Tumor microenvironment  \nIntroduction  \nThe human gastrointestinal tract hosts an extensive community of approximately 38 trillion microorganisms, primarily bacteria, which achieve their highest density within the colon [1]. This collective constitutes a complex ecosystem, often termed the \"second genome,\" due to its  \n†Siwei Min and Yue Zhang contributed equally to this work.  \n*Correspondence: Hao Zhang [haozhang@cmu.edu.cn](haozhang@cmu.edu.cn)[ ](haozhang@cmu.edu.cn)Qi Liu [qliu87@cmu.edu.cn](qliu87@cmu.edu.cn)  \n1Department of Clinical Medicine, The Second Clinical Medical School, China Medical University, Shenyang, China  \n2Department of Emergency, The First Hospital of China Medical University, Shenyang, China  \n3Department of Thyroid Surgery, The First Hospital of China Medical University, 155 Nanjing North Street, Shenyang, Liaoning Province, China  \nsignificant impact on host health, which arises from its intricate functions [2]. Gut microbiota (GM), through their extensive metabolic capabilities, engages in a symbiotic relationship with the host, playing a crucial role in regulating nutrient metabolism, immune function, and the integrity of the intestinal barrier [3, 4]. The microbiota performs essential functions both within the intestine and systemically. For instance, microbe-derived shortchain fatty acids (SCFAs), such as butyrate, contribute to the maintenance of the intestinal barrier by promoting mucus secretion and modulating pH levels. Additionally, SCFAs like butyrate directly and indirectly regulate immune homeostasis, thereby significantly enhancing the functional capacity of the host [5, 6].  \nRecent studies highlight the significant role of GM dysbiosis in promoting carcinogenesis. Colibactin, a genotoxin produced by adherent-invasive Escherichia coli (E.  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to ","cbCaiqrrOspvPEqv","https://ap.wps.com/l/cbCaiqrrOspvPEqv","pdf",2685131,"English","# Abstract\n# Introduction\n## Gut microbiota as a host regulator\n## Microbiota dysbiosis and carcinogenesis\n## Metabolites and immune modulation\n## Biomarkers and therapy implications","[{\"question\":\"How does gut microbiota influence cancer development and progression?\",\"answer\":\"Gut microbiota affects initiation and progression via metabolic reprogramming, virulence factor production, and immune microenvironment remodeling that can promote a pro-tumorigenic context.\"},{\"question\":\"What factors contribute to therapy resistance according to this review?\",\"answer\":\"Microbiota-driven metabolic dysregulation and altered immune microenvironment can support tumor evolution and reduce responsiveness to therapies.\"},{\"question\":\"What therapeutic strategies are proposed to overcome resistance?\",\"answer\":\"Strategies include modulating the microbiota by restoring ecological balance, enhancing anti-cancer immunity, and correcting metabolic dysregulation to improve clinical outcomes.\"}]","Gut microbiota drives cancer evolution and therapy resistance | PDF",1790116042,76,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7c1eb90fa434f3b25a29c421b3e15225.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e14a9ce615500bc90ebbc71452c6adb3.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4ab37cbd2810e8c902ad0b8125b6fd47.webp",981,1308,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9b2e3255ce123cfb906b38438b317d24.webp",980,1306]